⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935898 | 0.72 | — | — | |
| SCHEMBL7698743 | 0.72 | NOS3 (0.32) | — | |
| SCHEMBL178803 | 0.72 | NCF1 (0.39) | — | |
| SCHEMBL2487675 | 0.72 | — | — | |
| SCHEMBL772376 | 0.72 | DRD3 (0.33) | — | |
| SCHEMBL18060 | 0.71 | — | — | |
| SCHEMBL1035408 | 0.71 | NOS3 (0.36) | — | |
| SCHEMBL2104712 | 0.69 | HSD11B1 (0.35) | — | |
| SCHEMBL772535 | 0.69 | SPR (0.38) | — | |
| SCHEMBL18942541 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164854-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF | PHARMACYCLICS LLC | 2015-06-18 | — | — | US | claimed |
| WO-2013066833-A1 | COMPOUNDS AND METHODS TO INHIBIT HISTONE DEACETYLASE (HDAC) ENZYMES | GLAXOSMITHKLINE LLC (US) | 2013-05-10 | — | — | WO | claimed |
| EP-2319829-A1 | 9-substituted tetracycline compounds | Paratek Pharmaceuticals, Inc. (US) | 2011-05-11 | — | — | EP | claimed |
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| WO-2010123507-A1 | TREATMENT OF NON-LOCALIZED INFLAMMATION WITH PAN-HDAC INHIBITORS | PHARMACYCLICS, INC. (US) | 2010-10-28 | — | — | WO | claimed |
| US-20090270497-A1 | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors | PHARMACYCLICS, INC. (US) | 2009-10-29 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-7517988-B2 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| US-7482466-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2009-01-27 | — | — | US | claimed |
| US-20080255221-A1 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-7420089-B2 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | claimed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | claimed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | claimed |
| CN-101052620-A | Benzamide compound | ASTRAZENECA AB (SE) | 2007-10-10 | — | — | CN | claimed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | claimed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |